All Stories

  1. Beyond Nonverbal Learning Disability: The Case for and Against Developmental Visual–Spatial Disorder as a Distinct Diagnosis
  2. “Schizophrenia, Consciousness, and the Self” Twenty Years Later: Revisiting the Ipseity-Disturbance Model and the Developmental Nature of Self-Disorder in the Schizophrenia Spectrum
  3. Lack of transparency on baseline pharmacological treatments in Clinical High-Risk for psychosis (CHR-P) may degrade precision: A systematic review and meta-analysis
  4. Increasing conceptual clarity and confounders identification: a pragmatic way to enhance prognostic precision in ENIGMA clinical high risk for psychosis (CHR-P)
  5. Early intervention in eating disorders: introducing the chronopathogram
  6. L’espace vécu and Its Perturbations in Schizophrenia: Systematic Review and Meta-analysis of Altered Body-Centric Metrics—Personal and Peripersonal Space
  7. Baseline benzodiazepine exposure is associated with greater risk of transition in clinical high-risk for psychosis (CHR-P): a meta-analysis
  8. The temporal dynamics of transition to psychosis in individuals at clinical high-risk (CHR-P) shows negative prognostic effects of baseline antipsychotic exposure: a meta-analysis
  9. Faraway So Close: Schizophrenia and Dissociation From Clinical, Phenomenological, and Ontogenetic Viewpoints
  10. Clinical High Risk for Psychosis (CHR-P) in children and adolescents: a roadmap to strengthen clinical utility through conceptual clarity
  11. Neurodevelopmental Antecedents and Sensory Phenomena in Obsessive Compulsive Disorder: A Systematic Review Supporting a Phenomenological-Developmental Model
  12. Do antidepressants prevent transition to psychosis in individuals at clinical high-risk (CHR-P)? Systematic review and meta-analysis
  13. Vaccine Hesitancy, Anti-Vax, COVID-Conspirationism: From Subcultural Convergence to Public Health and Bioethical Problems
  14. Clinical high risk for psychosis in children and adolescents: A meta-analysis of transition prevalences
  15. From economic crisis and climate change through COVID-19 pandemic to Ukraine war: a cumulative hit-wave on adolescent future thinking and mental well-being
  16. Association between psychosocial interventions and aberrant salience in adolescents with early psychosis: A follow‐up study
  17. (Developmental) Motor Signs: Reconceptualizing a Potential Transdiagnostic Marker of Psychopathological Vulnerability
  18. Antipsychotics in Children and Adolescents at Clinical High Risk for Psychosis
  19. Examining subjective experience of aberrant salience in young individuals at ultra-high risk (UHR) of psychosis: A 1-year longitudinal study
  20. Through the prism of comorbidity: A strategic rethinking of early intervention in obsessive-compulsive disorder
  21. Identifying adolescents in the early stage of psychosis: A screening checklist for referrers
  22. Aberrant salience in first‐episode psychosis: Longitudinal stability and treatment‐response
  23. Letter to the Editor: Skin-Testing for Clones—Pediatric Obsessive Compulsive Disorder with Misidentification Syndrome
  24. Applying Transgenerational Scientific Evidence to the Next Wave of Early Identification Strategies for Psychopathological Risk—Transdiagnostic, Developmental, and Personalized
  25. Individualized Diagnostic and Prognostic Models for Psychosis Risk Syndromes: Do Not Underestimate Antipsychotic Exposure
  26. Reply to: Individualized Diagnostic and Prognostic Models for Psychosis Risk Syndromes: Do Not Underestimate Antipsychotic Exposure
  27. Subjective experience of aberrant salience in young people at Ultra-High Risk (UHR) for psychosis: a cross-sectional study
  28. Editorial Perspective: Psychosis risk in adolescence – outcomes, comorbidity, and antipsychotics
  29. Along the fringes of Agency: neurodevelopmental account of the obsessive mind
  30. Negative Prognostic Effect of Baseline Antipsychotic Exposure in Clinical High Risk for Psychosis (CHR-P): Is Pre-Test Risk Enrichment the Hidden Culprit?
  31. ANHEDONIA IN THE PSYCHOSIS RISK SYNDROME: STATE AND TRAIT CHARACTERISTICS
  32. Towards a phenomenological and developmental clinical staging of the mind with psychosis
  33. Early intervention in psychiatry through a developmental perspective
  34. Coronavirus Disease 2019 and Effects of School Closure for Children and Their Families
  35. The Self in the Spectrum: A Meta-analysis of the Evidence Linking Basic Self-Disorders and Schizophrenia
  36. Antipsychotic treatment in clinical high risk for psychosis: Protective, iatrogenic or further risk flag?
  37. Familiarity for Serious Mental Illness in Help-Seeking Adolescents at Clinical High Risk of Psychosis
  38. Editorial Perspective: Rethinking child and adolescent mental health care after COVID‐19
  39. Overcoming the gap between child and adult mental health services: The Reggio Emilia experience in an early intervention in psychosis program
  40. Attenuated Psychosis Syndrome or Pharmacologically Attenuated First-Episode Psychosis?
  41. Negative symptom dimensions in first episode psychosis: Is there a difference between schizophrenia and non‐schizophrenia spectrum disorders?
  42. Meta-analyzing the prevalence and prognostic effect of antipsychotic exposure in clinical high-risk (CHR): when things are not what they seem
  43. Psychological Support to the Community During the COVID-19 Pandemic: Field Experience in Reggio Emilia, Northern Italy
  44. Managing COVID‐19‐related psychological distress in health workers: Field experience in northern Italy
  45. Looking at Intergenerational Risk Factors in Schizophrenia Spectrum Disorders: New Frontiers for Early Vulnerability Identification?
  46. Assessing aberrant salience in young community help‐seekers with early psychosis: The approved Italian version of the Aberrant Salience Inventory
  47. Childhood schizotypal features vs. high-functioning autism spectrum disorder: Developmental overlaps and phenomenological differences
  48. Hey teachers! Do not leave them kids alone! Envisioning schools during and after the coronavirus (COVID-19) pandemic
  49. Advances in early identification of children and adolescents at risk for psychiatric illness
  50. Subjective experience of social cognition in young people at Ultra-High Risk of psychosis: a 2-year longitudinal study
  51. Disembodiment and schizophrenia: Looking at the motor roots of minimal self disorders in a developmental perspective
  52. Developmental Psychotic Risk: Toward a Neurodevelopmentally Informed Staging of Vulnerability to Psychosis
  53. Suicide risk in young people at Ultra-High Risk (UHR) of psychosis: Findings from a 2-year longitudinal study
  54. Suicidal thinking and behaviours in First Episode Psychosis: Findings from a 3‐year longitudinal study
  55. Letter to the editor: Evidence on school closure and children’s social contact: useful for coronavirus disease (COVID-19)?
  56. Anhedonia in young people with first episode psychosis: a longitudinal study
  57. Subjective experience of social cognition in adolescents at ultra-high risk of psychosis: findings from a 24-month follow-up study
  58. Overlooking the transition elephant in the ultra-high-risk room: are we missing functional equivalents of transition to psychosis?
  59. Obsessively thinking through the schizophrenia spectrum: Disentangling pseudo-obsessive schizophrenia from OCD
  60. Impaired Corollary Discharge in Psychosis and At-Risk States: Integrating Neurodevelopmental, Phenomenological, and Clinical Perspectives
  61. Developmental dynamic interplay between executive functions and psychotic risk
  62. The “Reggio Emilia At‐Risk Mental States” program: A diffused, “liquid” model of early intervention in psychosis implemented in an Italian Department of Mental Health
  63. Anhedonia in adolescents at ultra-high risk (UHR) of psychosis: findings from a 1-year longitudinal study
  64. Social dysfunction in preclinical, at risk stages of psychosis: A developmental view
  65. Suicidal Thinking and Behavior in Adolescents at Ultra‐High Risk of Psychosis: A Two‐year Longitudinal Study
  66. Intruding Thoughts: Between Obsessions and Hallucinations
  67. Uncanny Mirroring: A Developmental Perspective on the Neurocognitive Origins of Self-Disorders in Schizophrenia
  68. Clinical high risk for psychosis in childhood and adolescence: findings from the 2-year follow-up of the ReARMS project
  69. Considerations on Retrospective Identification and Classification of Learning Disabilities
  70. Polygenic Risk Score and the (neuro)developmental ontogenesis of the schizophrenia spectrum vulnerability phenotypes
  71. Rethinking the Psychosis Threshold in Clinical High Risk
  72. Calculation of the sound field due to circular rigid and resilient disks using spherical expansions.
  73. Motor Impairment and Developmental Psychotic Risk: Connecting the Dots and Narrowing the Pathophysiological Gap
  74. Clinical Implications of Slower Cognitive Growth in the Psychosis Spectrum
  75. Editorial Perspective: From schizophrenia polygenic risk score to vulnerability (endo‐)phenotypes: translational pathways in child and adolescent mental health
  76. A research framework to isolate visuospatial from childhood motor coordination phenotypes
  77. 28.2 DISORDERS OF THE EMBODIED SELF IN SCHIZOPHRENIA: AT THE CROSSROAD BETWEEN DEVELOPMENT AND PSYCHOPATHOLOGY
  78. Screening for psychosis risk among help‐seeking adolescents: Application of the Italian version of the 16‐item prodromal questionnaire (iPQ‐16) in child and adolescent neuropsychiatry services
  79. Corollary Discharge and Psychosis—Origin of the Model—Reply
  80. Stably positive Lyapunov exponents for symplectic linear cocycles over partially hyperbolic diffeomorphisms
  81. The Italian Version of the Brief 21-Item Prodromal Questionnaire: Field Test, Psychometric Properties and Age-Sensitive Cut-Offs
  82. Corollary Discharge, Self-agency, and the Neurodevelopment of the Psychotic Mind
  83. Internet of Things as a means to improve agricultural sustainability
  84. Architecture of change: rethinking child and adolescent mental health
  85. Rethinking Social Agent Representation in the Light of Phenomenology
  86. The dark side of dopaminergic therapies in Parkinson’s disease: shedding light on aberrant salience
  87. Schizophrenia polygenic risk score and psychotic risk detection
  88. Developmental Coordination Disorder Plus Oculomotor and Visuospatial Impairment as Neurodevelopmental Heralds of Psychosis Proneness
  89. Cognitive Clusters in Specific Learning Disorder
  90. Detecting dysexecutive syndrome in neurodegenerative diseases: are we using an appropriate approach and effective diagnostic tools?
  91. Definition of a visuospatial dimension as a step forward in the diagnostic puzzle of nonverbal learning disability
  92. Cortical thickness in de novo patients with Parkinson disease and mild cognitive impairment with consideration of clinical phenotype and motor laterality
  93. Migraine features in migraineurs with and without anxiety–depression symptoms: A hospital-based study
  94. Concomitant development of hypersexuality and delusional jealousy in patients with Parkinson's disease: A case series
  95. WISC-IV Intellectual Profiles in Italian Children With Specific Learning Disorder and Related Impairments in Reading, Written Expression, and Mathematics
  96. A pilot psychometric study of aberrant salience state in patients with Parkinson’s disease and its association with dopamine replacement therapy
  97. Mild Depressive Symptoms are Associated With Enhanced Affective Theory of Mind in Nonclinical Adult Women
  98. Progression of brain atrophy in the early stages of Parkinson's disease: A longitudinal tensor-based morphometry study in de novo patients without cognitive impairment
  99. Validation and attempts of revision of the MDS-recommended tests for the screening of Parkinson's disease dementia
  100. Diagnosis of possible Mild Cognitive Impairment in Parkinson's disease: Validity of the SCOPA-Cog
  101. The development of delusion revisited: A transdiagnostic framework
  102. A Single-Center, Cross-Sectional Prevalence Study of Impulse Control Disorders in Parkinson Disease
  103. Affective theory of mind in patients with Parkinson's disease
  104. Reply: Dopamine agonists and delusional jealousy in Parkinson's disease: A cross‐sectional prevalence study
  105. Corticobasal Syndrome Presenting With Partial Gerstmann’s Syndrome and Digit Agnosia
  106. From Aberrant Salience to Jumping to Conclusions
  107. Progressive Impairment of Decision-Making in Behavioral-Variant Frontotemporal Dementia
  108. Cognitive correlates of negative symptoms in behavioral variant frontotemporal dementia: implications for the frontal lobe syndrome
  109. How Aware Are Migraineurs of Their Triggers?
  110. Validity and metric of MiniMental Parkinson and MiniMental State Examination in Parkinson’s disease
  111. The relationship between motor symptom lateralization and cognitive performance in newly diagnosed drug-naïve patients with Parkinson's disease
  112. Neural and behavioral substrates of subtypes of Parkinson’s disease
  113. Psychometric properties of the Italian version of the Scales for Outcomes in Parkinson�s disease-in Parkinson�s disease-Cognition (SCOPA-Cog)
  114. Psychometric properties of the Italian version of the Scales for Outcomes in Parkinson�s disease-in Parkinson�s disease- Cognition (SCOPA-Cog)
  115. Diagnosis, assessment and management of delusional jealousy in Parkinson’s disease with and without dementia
  116. Triggers in Allodynic and Non‐Allodynic Migraineurs. A Clinic Setting Study
  117. Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson’s disease: a review
  118. Prefrontal cortex, dopamine, and jealousy endophenotype
  119. Behavioral and Psychological Symptoms of Dementia: Factor Analysis and Relationship with Cognitive Impairment
  120. Alteration of affective Theory of Mind in amnestic mild cognitive impairment
  121. Dopamine agonists and delusional jealousy in Parkinson's disease: A cross‐sectional prevalence study
  122. Mild cognitive impairment in De Novo Parkinson's disease according to movement disorder guidelines
  123. Mild affective symptoms in de novo Parkinson's disease patients: relationship with dopaminergic dysfunction
  124. Alexithymia Is Associated With Impulsivity in Newly-Diagnosed, Drug-Naïve Patients With Parkinson’s Disease: An Affective Risk Factor for the Development of Impulse-Control Disorders?
  125. Cognitive and affective Theory of Mind in neurodegenerative diseases: Neuropsychological, neuroanatomical and neurochemical levels
  126. Relationship Between Neuropsychiatric Symptoms and Cognitive Performance in De Novo Parkinson’s Disease
  127. The “Closing-In” Phenomenon in Parkinson’s Disease Dementia and Lewy-Body Dementia
  128. Affective symptoms and cognitive functions in Parkinson's disease
  129. Orbital and ventromedial prefrontal cortex functioning in Parkinson’s disease: Neuropsychological evidence
  130. Impulse control disorders in Parkinson’ disease: the role of personality and cognitive status
  131. Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naive patients with Parkinson's disease
  132. Impairment of Affective Theory of Mind in Corticobasal Degeneration
  133. Personality traits in patients with Parkinson’s disease: assessment and clinical implications
  134. Iowa gambling task in de novo Parkinson's disease: A comparison between good and poor performers
  135. Event-Based Prospective Memory in Newly Diagnosed, Drug-Naive Parkinson's Disease Patients
  136. Mild cognitive impairment and cognitive reserve in Parkinson’s disease
  137. Impulsivity Is Associated With Decision-Making Deficits in De-Novo Parkinson's Disease
  138. Theory of Mind in Parkinson's disease
  139. The neuropsychological correlates of pathological lying: evidence from behavioral variant frontotemporal dementia
  140. Decision-Making Impairment May Precede Limb Apraxia in Corticobasal Degeneration
  141. Impulsivity and compulsivity in drug‐naïve patients with Parkinson's disease
  142. Alexithymia Is Associated with Depression in de novo Parkinson’s Disease
  143. From Narcissistic Personality Disorder to Frontotemporal Dementia: A Case Report
  144. The association between motor subtypes and alexithymia in de novo Parkinson’s disease
  145. Iowa Gambling Task in Parkinson's Disease
  146. Decision making in de novo Parkinson's disease
  147. Out-of-Control Sexual Behavior in an Orbitofrontal Cortex-Damaged Elderly Patient
  148. Orbitofrontal cortex-related executive functions in children and adolescents: their assessment and its ecological validity
  149. Out-of-Control Sexual Behavior in an Orbitofrontal Cortex-Damaged Elderly Patient
  150. Decision-Making Impairment in a Patient With New Concomitant Diagnoses of Parkinson's Disease and HIV
  151. Decision-Making Impairment in a Patient With New Concomitant Diagnoses of Parkinson’s Disease and HIV
  152. Gestural buffer impairment in early onset Corticobasal Degeneration: a single-case study